

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	
Filing Date	March 31, 2004
First Named Inventor	Arzubi, Blas
Art Unit	
Examiner Name	
Attorney Docket Number	88885

Sheet 1 of 3

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US- 4,390,559	06- 28-1983	Zilliken	
		US- 4,414,157	11-08-1983	Iwama et al	
		US- 4,588,745	05-13-1986	Bessler	
		US- 5,453,523	09-26-1995	Weete et al.	
		US- 5,679,806	10-21-1997	Zheng et al	
		US- 5,703,255	12-30-1997	Weete et al.	
		US- 6,033,714	03-07-2000	Gugger, et al.	
		US- 6,171,638	01-09-2001	Gugger, et al.	
		US- 6,544,566	04-08-2003	Waggle, et al.	
		US- 6,562,380	05-13-2003	Kelly	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number

Filing Date

March 31, 2004

First Named Inventor

Blas Arzubi

Art Unit

Examiner Name

Sheet

2

of

3

Attorney Docket Number

88885

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BARNES, S. The Chemopreventive Properties of Soy Isoflavonoids in Animal Models of Breast Cancer. Breast Cancer Research and Treatment.	
		BARNES, S.; Peterson T.; Coward L. Rationale for the Use of Genistein Containing Soy Matrices in Chemoprevention Trials for Breast and Prostate Cancer. Journal of Cellular Bio	
		PETERSON T.; Barnes S. Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation. The P	
		SANTIBANEX J.; Navarro A.; Martínez J. Genistein Inhibits Proliferation and in Vitro Invasive Potential of Human Prostatic Cancer Cell Lines. Anticancer Research 17:1199-1204	
		GELLER J.; Sionit L.; Partido C.; Li L.; Tan X.; Youngkin T.; Nachtsheim D. Genistein Inhibits the Growth of Human-Patient BPH and Prostate Cancer in Histoculture. The Prostat	
		NAIK H.; Lehr J.; Pienta K. An in Vitro and in Vivo Study of Antitumor Effects of Genistein on Hormone Refractory Prostate Cancer. Anticancer Research 14:2617-2620 (1994)	
		LANDSTROM M.; Jie-Xian Zhang; Hallmans G.; Aman P.; Bergh A.; Damber Jan-Erik; Mazur W.; Wahala K.; Adlercreutz H. Inhibitory Effects of Soy and Rye Diets on the Development of	
		POLLARD M.; Luckert P. Influence of Isoflavones in Soy Protein Isolates on Development of Induced Prostate – related Cancers in L-W Rats. Nutrition and cancer. 28(1), 41-45	
		DALU A.; Haskell J.; Coward L.; Lamartiniere C. Genistein, a Component of Soy, Inhibits the Expression of the EGF and ErbB2/Neu Receptors in the Rat Dorsolateral Prostate. The	
		STEPHENS F. Phytoestrogens and Prostate Cancer: possible preventive role. MJA vol.167 Anderson John J.B; Garner Sanford C. The Effects of Phytoestrogens On Bone. Nutrition Res	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number			
		Filing Date	March 31, 2004		
		First Named Inventor	Arzubi, Blas		
		Art Unit			
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	88885

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ISHIDA H.; Uesugi T.; Hirai K.; Toda T.; Nukaya H.; Yokotsuka K.; Tsuji K. Preventive Effects of the Plant Isoflavones, Daidzin and Genistin on Bone Loss in Ovariectomized Rats	
		ARJAMANDI B.H.; Alekel, L.; Hollis B.W.; Amin D.; Stacewicz-Sapuntzakis M.; Guo P.; Kukreja S. C. Dietary Soybean Protein Prevents Bone Loss in an Ovariectomized Rat Model of O	
		ERDMAN J.W. Jr, PhD; Potter Susan M., PhD, R.D. Soy and Bone Health. The Soy Connection. Vol 5 No.2 (1997)	
		KOUDY Williams J.; Delansorne Remi; Paris J. Estrogens, Progestins and Coronary Artery reactivity in Atherosclerotic Monkeys. F. Steroid Biochem. Molec. Biol., Vol. 65, no.1-6	
		HONORE E.K.; Koudy Williams J.; Anthony Mary S.; Clarkson T.B. Soy isoflavones Enhance Coronary Vascular Reactivity in Atherosclerotic Female Macaques. Fertility and Sterility	
		NESTEL P.J.; Yomashita T.; Sasahara T.; Pomeroy Sylvia; Dart A.; Komesaroff P.; Owen Alice; Abbey M. Soy Isoflavones Improve Systemic Arterial Compliance but Not Plasma L	
		DALAIS F.S.; Ricel G.E.; Wahlquist M.L.; Grehan M.; Murkies A.L.; Medley G.; Ayton R.; Strauss B.J.G. Effects of Dietary Phytoestrogens in Postmenopausal Woman. Climateric 199	
		BRZEZINSKI A.; Adlercreutz H.; Shaoul R.; Rosler A.; Shmueli A.; Tanos V.; Schenker J.G. Short-term Effects of Phytoestrogen-rich Diet on Postmenopausal Woman. Menopause: V	
		ALBERTAZZI P.; Pansini F.; Bonaccorsi G.; Zanotti L.; Forini E.; De Aloysio D. The Effect of Dietary Soy Supplementation and Hot Flushes, Vol.91, No.1, Jan.98	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.